{"id":77574,"date":"2026-08-31T21:08:44","date_gmt":"2026-08-31T13:08:44","guid":{"rendered":"https:\/\/flcube.com\/?p=77574"},"modified":"2026-08-31T21:08:45","modified_gmt":"2026-08-31T13:08:45","slug":"westgene-and-create-sign-license-deal-to-co-develop-in-vivo-car-t-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=77574","title":{"rendered":"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>WestGene Biopharma<\/strong> and <strong>CREATE Medicines, Inc.<\/strong> announced a strategic license and collaboration agreement combining CREATE&#8217;s innovative <strong>mRNA\u2011CAR technology<\/strong> with WestGene&#8217;s <strong>targeted lipid nanoparticle (tLNP) delivery platform<\/strong> to co\u2011advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene&#8217;s internationalization of its LNP\/tLNP platform.<\/p>\n\n\n\n<h2 id=\"h-deal-structure\" class=\"wp-block-heading\">Deal Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Partners<\/td><td><strong>WestGene Biopharma<\/strong> and <strong>CREATE Medicines, Inc.<\/strong><\/td><\/tr><tr><td>Agreement Type<\/td><td>Strategic license and collaboration<\/td><\/tr><tr><td>Technologies<\/td><td>CREATE mRNA\u2011CAR technology + WestGene tLNP delivery platform<\/td><\/tr><tr><td>Programs<\/td><td>Three in vivo cell therapy candidates<\/td><\/tr><tr><td>Indications<\/td><td>Autoimmune diseases, hematologic malignancies, solid tumors<\/td><\/tr><tr><td>Date<\/td><td>31 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-territorial-rights-amp-economics\" class=\"wp-block-heading\">Territorial Rights &amp; Economics<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Component<\/th><th>Terms<\/th><\/tr><\/thead><tbody><tr><td>WestGene Rights<\/td><td>Exclusive development and commercialization in Mainland China, Hong Kong, Macau, and Taiwan<\/td><\/tr><tr><td>CREATE Rights<\/td><td>Exclusive development and commercialization globally outside Greater China<\/td><\/tr><tr><td>WestGene Economics<\/td><td>Early\u2011stage R&amp;D funding, upfront payment, development and commercialization milestones, plus royalties on future product sales<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-profile\" class=\"wp-block-heading\">Technology Profile<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CREATE mRNA\u2011CAR Technology:<\/strong> Enables in vivo generation of CAR\u2011T cells, eliminating the need for ex vivo cell manufacturing<\/li>\n\n\n\n<li><strong>WestGene tLNP Platform:<\/strong> Targeted lipid nanoparticle delivery system designed for cell\u2011type\u2011specific nucleic acid delivery<\/li>\n\n\n\n<li><strong>Combined Value Proposition:<\/strong> A fully in vivo approach to cell therapy that could dramatically reduce cost, complexity, and turnaround time versus personalized ex vivo CAR\u2011T manufacturing<\/li>\n\n\n\n<li><strong>Platform Positioning:<\/strong> The collaboration extends WestGene&#8217;s LNP\/tLNP platform into international partnerships, reinforcing its licensing strategy<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">The agreement follows WestGene&#8217;s stated push to internationalize its delivery platform, pairing proprietary tLNP targeting with CREATE&#8217;s mRNA\u2011CAR engineering. For a modality historically constrained by bespoke manufacturing, in vivo cell therapy promises an off\u2011the\u2011shelf profile that could unlock broader patient access across autoimmune disease and oncology.<\/p>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>In Vivo Cell Therapy Momentum:<\/strong> The field has become one of biotech&#8217;s hottest frontiers, with major pharma striking deals to secure delivery capabilities<\/li>\n\n\n\n<li><strong>Platform Validation:<\/strong> A cross\u2011border partnership validates WestGene&#8217;s tLNP technology as exportable intellectual property<\/li>\n\n\n\n<li><strong>Strategic Logic:<\/strong> Greater China \/ ex\u2011China rights split aligns each partner with its strongest regional development and commercial infrastructure<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> In vivo CAR\u2011T approaches aim to undercut the cost and logistics of ex vivo therapies while expanding into chronic autoimmune indications<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong> \u2014 This brief contains forward\u2011looking statements regarding the development, regulatory progress, and commercialization of collaboration products under the WestGene\u2013CREATE agreement. Actual results may differ materially due to risks inherent in drug development, regulatory review, and competitive dynamics. Readers should not place undue reliance on such statements.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE&#8217;s&#8230;<\/p>\n","protected":false},"author":1,"featured_media":77575,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10,4908],"tags":[4915,402],"class_list":["post-77574","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-pic","tag-create-medicines","tag-westgene-biopharma"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE&#039;s innovative mRNA\u2011CAR technology with WestGene&#039;s targeted lipid nanoparticle (tLNP) delivery platform to co\u2011advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene&#039;s internationalization of its LNP\/tLNP platform.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=77574\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies\" \/>\n<meta property=\"og:description\" content=\"WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE&#039;s innovative mRNA\u2011CAR technology with WestGene&#039;s targeted lipid nanoparticle (tLNP) delivery platform to co\u2011advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene&#039;s internationalization of its LNP\/tLNP platform.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=77574\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-31T13:08:44+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-31T13:08:45+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies\",\"datePublished\":\"2026-08-31T13:08:44+00:00\",\"dateModified\":\"2026-08-31T13:08:45+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101-1.webp\",\"keywords\":[\"CREATE Medicines\",\"WestGene Biopharma\"],\"articleSection\":[\"Company\",\"Deals\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77574#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=77574\",\"name\":\"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101-1.webp\",\"datePublished\":\"2026-08-31T13:08:44+00:00\",\"dateModified\":\"2026-08-31T13:08:45+00:00\",\"description\":\"WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE's innovative mRNA\u2011CAR technology with WestGene's targeted lipid nanoparticle (tLNP) delivery platform to co\u2011advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene's internationalization of its LNP\\\/tLNP platform.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=77574\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/08\\\/3101-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=77574#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE's innovative mRNA\u2011CAR technology with WestGene's targeted lipid nanoparticle (tLNP) delivery platform to co\u2011advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene's internationalization of its LNP\/tLNP platform.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=77574","og_locale":"en_US","og_type":"article","og_title":"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies","og_description":"WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE's innovative mRNA\u2011CAR technology with WestGene's targeted lipid nanoparticle (tLNP) delivery platform to co\u2011advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene's internationalization of its LNP\/tLNP platform.","og_url":"https:\/\/flcube.com\/?p=77574","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-31T13:08:44+00:00","article_modified_time":"2026-08-31T13:08:45+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=77574#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=77574"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies","datePublished":"2026-08-31T13:08:44+00:00","dateModified":"2026-08-31T13:08:45+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=77574"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=77574#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101-1.webp","keywords":["CREATE Medicines","WestGene Biopharma"],"articleSection":["Company","Deals","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=77574#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=77574","url":"https:\/\/flcube.com\/?p=77574","name":"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=77574#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=77574#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101-1.webp","datePublished":"2026-08-31T13:08:44+00:00","dateModified":"2026-08-31T13:08:45+00:00","description":"WestGene Biopharma and CREATE Medicines, Inc. announced a strategic license and collaboration agreement combining CREATE's innovative mRNA\u2011CAR technology with WestGene's targeted lipid nanoparticle (tLNP) delivery platform to co\u2011advance three in vivo cell therapy programs. The partnership targets autoimmune diseases, hematologic malignancies, and solid tumors, marking another milestone in WestGene's internationalization of its LNP\/tLNP platform.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=77574#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=77574"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=77574#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101-1.webp","width":1080,"height":608,"caption":"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=77574#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"WestGene and CREATE Sign License Deal to Co\u2011Develop In Vivo CAR\u2011T Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/08\/3101-1.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77574","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=77574"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77574\/revisions"}],"predecessor-version":[{"id":77576,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/77574\/revisions\/77576"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/77575"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=77574"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=77574"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=77574"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}